



State of Oklahoma **SoonerCare** 

## Camcevi<sup>®</sup> (Leuprolide) Prior Authorization Form

Member Name:	Date of Birth:	Member ID#:		
Drug Information				
□Physician billing (HCPCS code:_	) □Pharmacy k	billing (NDC:)		
Start Date (or date of next dose):	Dose:			
Dosing Regimen:				
Billing Provider Information				
Provider NPI:				
Provider Phone: Provider Fax:				
Prescriber Information				
Prescriber NPI:				
Prescriber Phone:		Specialty:		
Criteria				
<ul> <li>For Initial Authorization</li> <li>1. Please indicate the diagnosis and information: <ul> <li>Advanced Prostate Cancer</li> <li>A. Please provide a patient-specific, clinically significant reason the member cannot use each of the following (for Camcevi<sup>®</sup> authorization consideration, reasons must be provided for each alternative listed): <ul> <li>1. Eligard<sup>®</sup> (leuprolide acetate):</li> <li>2. Firmagon<sup>®</sup> (degarelix):</li> <li>3. Lupron Depot<sup>®</sup> (leuprolide acetate):</li> </ul> </li> <li>If diagnosis is not listed of the above, please indicate diagnosis:</li> </ul></li></ul>				
Additional Information:         For Continued Authorization:         1. Date of last dose:         2. Does the member have any evidence of progressive disease while on Camcevi®? Yes         3. Has the member experienced adverse drug reactions related to Camcevi® therapy? Yes         If yes, please specify adverse reactions:         Additional Information:         Prescriber Signature:         I certify that the indicated treatment is medically necessary and all information is true and correct to the best of my				
<b>knowledge.</b> Failure to complete this form in full will result in processing delays.				

Fax completed prior authorization request form to 888-601-8461 or submit Electronic Prior Authorization through CoverMyMeds® or SureScripts. All requested data must be provided. Incomplete forms or forms without the chart notes will be returned. Pharmacy Coverage Guidelines are available at AetnaBetterHealth.com/Oklahoma.

	NOTICE
	NUTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.